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The nuclear bile acid receptor FXR is critical for regu-
lationof lipidandglucosemetabolism.Here,we report
that FXR is a target of SIRT1, a deacetylase thatmedi-
ates nutritional and hormonal modulation of hepatic
metabolism. Lysine 217 of FXR is the major acetyla-
tion site targeted by p300 and SIRT1. Acetylation of
FXR increases its stability but inhibits heterodimeriza-
tion with RXRa, DNA binding, and transactivation
activity. Downregulation of hepatic SIRT1 increased
FXRacetylationwithdeleteriousmetabolicoutcomes.
Surprisingly, in mouse models of metabolic disease,
FXR interactionwithSIRT1andp300wasdramatically
altered, FXR acetylation levels were elevated, and
overexpression of SIRT1 or resveratrol treatment
reduced acetylated FXR levels. Our data demonstrate
thatFXRacetylation isnormallydynamically regulated
by p300 and SIRT1 but is constitutively elevated in
metabolic disease states. Small molecules that inhibit
FXR acetylation by targeting SIRT1 or p300 may be
promising therapeutic agents formetabolic disorders.
INTRODUCTION
Farnesoid X receptor (FXR) is a ligand-regulated transcription
factor that belongs to a large superfamily of nuclear receptors
(Mangelsdorf and Evans, 1995). Activated by physiological
concentrations of bile acids, FXR regulates expression of
numerous bile acid-responsive genes, mainly in the liver and
intestine, to regulate cholesterol and bile acid homeostasis (Car-
iou and Staels, 2007; Kalaany and Mangelsdorf, 2006; Lee et al.,
2006). Other studies have established that FXR is also a master
regulator of lipid and glucose homeostasis (Lee et al., 2006; Ma
et al., 2006) and is critically involved in liver regeneration (Huang
et al., 2006) and protection of intestines from intestinal bacteria
growth (Inagaki et al., 2006). Disruption of the FXR gene in trans-
genic mice is associated with metabolic diseases, including
diabetes and hypercholesterolemia (Sinal et al., 2000). Of392 Cell Metabolism 10, 392–404, November 4, 2009 ª2009 Elsevierinterest, activation of FXR in diabetic mice improved metabolic
outcomes by reducing serum glucose and lipid levels (Zhang
et al., 2006). Although these critical roles of FXR in normal phys-
iology and metabolic disease processes have been established,
the molecular basis of how FXR activity is modulated in health
and disease states remains largely unexplored.
Nuclear receptors collaborate with numerous transcriptional
cofactors to effectively modulate transcription of their target
genes (Rosenfeld et al., 2006). Transcriptional regulation by
nuclear receptors, therefore, involves the recruitmentof cofactors
to target gene promoters that results in histone modification. In
addition, these cofactors alsomodulate receptor activity by post-
translational modification of the receptor itself, including acetyla-
tion and deacetylation. Previous studies have shown that the
activities of regulatory proteins, such as PGC-1a, Foxo-1, LXR,
and p53, are modulated by protein acetylation and deacetylation
(Daitoku et al., 2004; Kitamura et al., 2005; Lerin et al., 2006;
Li et al., 2007; Luo et al., 2001; Motta et al., 2004; Rodgers
et al., 2005). We recently reported that p300 acetylates FXR, as
well as histones at FXR target gene promoters (Fang et al.,
2008), but the role of FXR acetylation in normal and metabolic
disease states remains unclear.
A mammalian homolog of yeast sir2, SIRT1, regulates cellular
metabolism such that aging and life longevity are affected (Guar-
ente, 2007; Sinclair et al., 2006). SIRT1 is a NAD+-dependent
deacetylase that removes acetyl groups from modified lysine
residues in both histones and transcription factors (Sinclair
et al., 2006). Recent studies demonstrate that SIRT1 plays an
important role in the regulation of metabolism in response to
hormonal and nutritional cues by modulating the activity of
PGC-1a, a master metabolic regulator (Rodgers et al., 2005,
2008). For instance, whereas acetylation of PGC-1a by GCN5
acetylase decreased PGC-1a activity by altering its intranuclear
distribution, deacetylation of PGC-1a by SIRT1 increased its
activity (Lerin et al., 2006; Rodgers et al., 2005). Of interest, acti-
vation of SIRT1 by a polyphenolic compound, resveratrol, in
mouse models of metabolic disease reduced acetylation levels
of PGC-1a and improved metabolic profiles (Baur et al., 2006;
Lagouge et al., 2006).
Both FXR and SIRT1 are critically involved in liver metabolic
regulation (Lee et al., 2006; Lerin et al., 2006; Rodgers andInc.
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FXR Acetylation in Normal and Disease StatesPuigserver, 2007; Zhang et al., 2004), and activation of these
proteins in mouse models of metabolic disease improved meta-
bolic outcomes (Baur et al., 2006; Lagouge et al., 2006; Zhang
et al., 2006). Therefore, these previous studies, along with our
recent findings that FXR is acetylated by p300 (Fang et al.,
2008), prompted us to ask whether SIRT1 modulates the activity
of FXR by deacetylation. Using molecular, cellular, and animal
in vivostudies,we investigated thebiological functionof FXRacet-
ylation in normal and metabolic disease states. Here, we demon-
strate that FXR is a target of SIRT1 in metabolic regulation. Acety-
lation of FXR inhibits its activity and is dynamically regulated by
p300 and SIRT1 under normal conditions. Downregulation
of hepatic SIRT1 by siRNA increased FXR acetylation with
deleterious metabolic outcomes. Surprisingly, FXR acetylation
levels were constitutively elevated in two mouse models of
metabolic disorders, ob/ob mice and mice chronically fed a
western-style diet. Treatment with the SIRT1 activator resveratrol
or adenoviral-mediated overexpression of SIRT1 substantially
reduced FXR acetylation levels in these disease model mice. Our
studies provide an intriguing correlation between elevated FXR
acetylationbydecreasedSIRT1activity, decreasedFXRactivities,
and deleterious metabolic effects in hepatic metabolic disease.
RESULTS
K217 in the Hinge Region of FXR Is the Major
Acetylation Site
As the first step in defining the functional role of FXR acetylation,
we identified lysine (K) residues acetylated using tandem mass
spectrometry (MS/MS). Flag-tagged FXR was expressed in
HepG2 cells, and isolated flag-FXR was acetylated by p300
in vitro (Figures 1A–1C). The MS/MS analysis revealed that K217
in the hinge region was themajor site acetylated and that K157 in
the DNA-binding domain was also acetylated (Figures 1D and 1E
and Figure S1 available online). K217 is highly conserved in FXR
in vertebrates (Figure 1F).
To confirm these results, we cotransfected cells with plasmids
for p300 and either FXR or one of the acetylation-defective FXR
mutants, K157R and K217R. Acetylated FXR was detected by
immunoprecipitation under stringent conditions with buffers
containing SDS, followed bywestern analysis using an anti-acetyl
lysine antibody. FXR acetylation levels were increased by treat-
ment with deacetylase inhibitors trichostatin A (TSA) and nicotin-
amide (Nam) (Figure 1G, lanes 2 and 4), suggesting that FXR
undergoes dynamic acetylation and deacetylation. Treatment
with GW4064, a synthetic FXR agonist (Willson et al., 2001),
modestly increased FXR acetylation (Figure 1G, lanes 3 and 4).
FXR acetylation levels were substantially reduced in the K217R
mutant and nearly abolished in the K157/217R double mutant
(Figure 1G, lanes 4–7). These results indicate that K217 of FXR is
themajor acetylation sitebyp300and thatK157 isalsoacetylated.
Acetylation of FXR Increases Its Stability
Because FXR protein levels of the acetylation mutants were
markedly reduced (Figure 1G), we tested whether acetylation
of FXR affects its stability. Treatment with MG132, a proteasome
inhibitor, dramatically increased FXR levels and resulted in its
ubiquitination in vitro and in cells (Figures 2A, 2B, S2, and S3).
The degradation rate was determined by monitoring theCell Mdecrease of flag-FXR wild-type or mutants after blocking protein
synthesis by cycloheximide (CHX). The half-lives were 5–6 hr for
ligand-activated flag-FXRwild-type and about 2 hr for the K157R
or K217R mutants (Figure 2C), indicating that FXR acetylation
increases its stability. These results suggest that FXR is a target
of ubiquitin-proteasomal degradation, and acetylation of FXR
increases protein stability by inhibiting its degradation.
Mutation of FXR Acetylation Sites Increases
Transactivation
To determine whether acetylation of FXR affects its transactiva-
tion ability, the effects of mutation of K157 and/or K217 on FXR
transactivation were examined. Overexpression of K157R and
K217R mutants increased FXR activity compared to wild-type,
and mutation of both sites synergistically increased FXR trans-
activation activity at the lower amounts of plasmids transfected
(Figure 2D, lanes 2, 4, 6, and 8). Mutation of K122 to arginine
did not alter FXR acetylation levels (data not shown) and had
little effect on FXR transactivation (Figure 2D, lanes 3 and 10).
In the absence of activation of FXR byGW4046, little transactiva-
tion was observed (Figure 2E). Mutation of K157 and K217 to
glutamine residues (Q) to mimic acetylation resulted in transacti-
vation by FXR similar to that of the wild-type (Figure 2E, lanes 4
and 8). Similar results were observed in reporter assays using
a natural SHP promoter-luc (Figure 2F). With both reporters,
the effects of the K217 mutant were greater than those of the
K157 mutant.
We also examined the effects of FXR acetylation on expres-
sion of the endogenous SHP gene in HepG2 cells. The mRNA
levels of SHP were significantly increased when the K157/217R
mutant was coexpressed with p300 (Figure 2G). These results
indicate that FXR transactivation activity is decreased when
FXR is acetylated.
Mutation of K157 and K217 Increases Binding
of FXR/RXRa Heterodimer to DNA
Because FXR activity was decreased by acetylation of FXR, we
tested whether acetylation alters binding of the FXR/RXR heter-
odimer to the DNA. Cells were cotransfected with p300 along
with different amounts of expression plasmids for flag-FXR or
the K157/K217 mutant to yield similar protein expression levels
(Figure 3A). Acetylation of FXR was reduced in the K157/K217
mutant compared to wild-type (Figure 3A, bottom). Antibody
supershift gel mobility shift assays identified the FXR/RXR/
DNA complexes (Figure 3B, lanes 10–13). Although little binding
of wild-type FXR was observed, robust DNA binding was
detected with the K157/K217R mutant (Figure 3B, lanes 4–6
and 7–9). These results suggest that FXR acetylation inhibits
binding of FXR/RXRa to DNA.
To directly test the effect of acetylation of FXR on its DNA
binding, purified flag-FXR was acetylated by p300 in vitro, and
acetylation of flag-FXR was confirmed (Figures 3C and 3D). In
gel shift assays, a single protein/DNA complex was detected,
which was supershifted by the M2 and FXR antibodies
(Figure 3E, lanes 4–7). Binding of unacetylated FXR/RXRwas de-
tected in a dose-dependent manner (Figure 3E, lanes 8–13 and
17–22), whereas binding of acetylated FXR was substantially
reduced (Figure 3E, lanes 14–16 and 23–25). Addition of
GW4064 resulted in increased DNA binding of the unacetylatedetabolism 10, 392–404, November 4, 2009 ª2009 Elsevier Inc. 393
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FXR Acetylation in Normal and Disease StatesFigure 1. The Major Site Acetylated in FXR by p300 Is K217
(A) Experimental outline.
(B andC) After incubationwith p300, proteins were separated using SDS-PAGE and stained by colloidal Coomassie blue (B), or acetylated flag-FXRwas detected
by western analysis (C). In the bottom panel of (C), the membrane was stripped and reprobed with FXR antibody. An asterisk denotes IgG heavy chain.
(D) Tandem MS (MS/MS) spectrum of the FXR peptide showing acetylation at K217.
(E) A schematic diagram of acetylation sites in FXR.
(F) Alignment of the FXR region containing K217 from various species.
(G) Cos-1 cells transfected with p300 and with flag-FXR (f-FXR) plasmids were treated as indicated for 2 hr. Flag-FXR was immunoprecipitated, and acetylated
FXR was detected by western analysis.394 Cell Metabolism 10, 392–404, November 4, 2009 ª2009 Elsevier Inc.
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FXR Acetylation in Normal and Disease StatesFXR (Figure 3E, lanes 8–13 and 17–22) but had little effect on
binding of acetylated FXR (Figure 3E, lanes 14–16 and 23–25).
These results demonstrate that binding of FXR/RXR to the
DNA is inhibited when FXR is acetylated.
FXR Acetylation Inhibits FXR/RXRa Heterodimerization
Because DNA binding of FXR/RXR could be impaired if forma-
tion of FXR/RXRa heterodimers is blocked, we examined the
effects of mutation of K157 and K217 on the interaction of FXR
with RXRa in cells coexpressing p300. RXRawas coimmunopre-
cipitated with the FXR acetylation mutants, whereas RXRa
was not detected in FXR immunoprecipitates of wild-type FXR
(Figures 3F, 3G, and S4). These results indicate that FXR acety-
lation inhibits FXR/RXRa heterodimerization.
Because FXR acetylation decreases heterodimerization and
DNA binding of FXR/RXR, acetylation effects on its transactiva-
tion ability should be reduced in FXR fused to aGal4DNA-binding
domain (G4DBD). Binding to a Gal4 promoter reporter should be
independent of heterodimerization. In contrast to the enhanced
transactivation ability in (FXRE)3-tk-luc (Figures 2D and 2E) or
SHP promoter-luc (Figure 2F), expression of G4DBD-K217R
did not significantly increase its transactivation (FigureS5). These
results, togetherwith gel shift assays andCoIPprotein interaction
Figure 2. FXR Acetylation Increases Its Stability
but Inhibits Transactivation Ability
(A) HepG2 cells infected with Ad-flag-FXR were treated
with vehicle orMG132, and flag-FXR levels were detected.
(B) HepG2 cells were cotransfected with expression plas-
mids as indicated. Flag-FXR was immunoprecipitated
from cell extracts, and ubiquitinated flag-FXR was de-
tected.
(C) Transfected Cos-1 cells were treated with CHX for the
indicated times, and flag-FXR levels in cell extracts were
detected.
(D–F) HepG2 cells were cotransfected with indicated
reporter plasmids and expression plasmids for p300 and
FXR WT or FXR mutants, as indicated. Cells were treated
with 200 nM of GW4064 overnight. The values for firefly
luciferase activities were normalized by dividing by b-
galactosidase activities.
(G) HepG2 cells were cotransfected with plasmids as indi-
cated and treated with GW4064. The mRNA levels were
determined by q-RTPCR. Statistical significance was
measured using the Student’s t test.
*p < 0.05; **p < 0.01; NS, statistically not significant. Error
bars, SEM. n = 3.
studies, demonstrate that FXR acetylation
inhibits FXR/RXRa heterodimerization, which
accounts for, at least in part, impaired binding
of FXR/RXR to the DNA and reduced FXR trans-
activation ability.
SIRT1 Is Associated with FXR in Mouse
Liver In Vivo
The level of acetylation of FXR is likely to be
a balance between acetylation and deacetyla-
tion of the protein. The SIRT1 deacetylase is
emergingas amastermetabolic regulator (Guar-
ente,2007;Rodgersetal.,2008)and isapossible
candidate for modulating FXR acetylation. Therefore, we exam-
ined whether SIRT1 associates with FXR in mouse liver. In CoIP
assays, the amount of SIRT1 associated with flag-FXR was
substantially reduced in mice fed cholic acid (CA), a primary bile
acid and natural FXR agonist (Figure S6). To determine whether
overexpression of flag-FXR resulted in nonspecific interaction
with SIRT1, we also examined the interaction between endoge-
nous SIRT1 and endogenous FXR. CA feeding reduced the inter-
actionof endogenousFXRwithSIRT1 (Figure 4A). Similarly, treat-
ment with GW4046 reduced the interaction of FXR and SIRT1 in
mouse liver (Figure 4B) and in cultured cells (Figure S7). In addi-
tion, the interaction of FXR with SIRT1 was substantially
increased by fasting (Figures 4C and S8). Conversely, FXR inter-
action with p300 was substantially increased after feeding
(Figure S9). These results demonstrate that FXR and SIRT1
interact in mouse liver and that the interaction is decreased by
activation of FXR or in response to feeding.
SIRT1 Directly Interacts with and Deacetylates FXR
The CoIP studies demonstrate that FXR and SIRT1 interact
directly or indirectlywithin acomplex.Wenext examinedwhether
SIRT1 can bind directly to FXR using GST pull-downs. FXR inter-
acted with full-length GST-SIRT1 and with the GST-SIRT1Cell Metabolism 10, 392–404, November 4, 2009 ª2009 Elsevier Inc. 395
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FXR Acetylation in Normal and Disease StatesFigure 3. Acetylation of FXR Inhibits Binding of FXR/RXRa to DNA
(A) Flag-FXR (top) or acetylated flag-FXR (bottom) was detected in Cos-1 cell extracts.
(B) Increasing amounts of cell extracts were incubated with flag-RXRa and the radiolabeled oligonucleotide probe containing the FXRE from the SHP promoter,
and complexes were detected using gel mobility shift (gms) assay.
(C) Experimental outline for the gms using flag-FXR acetylated in vitro.396 Cell Metabolism 10, 392–404, November 4, 2009 ª2009 Elsevier Inc.
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FXR Acetylation in Normal and Disease Statesfragment (214–441),which contains the sirtuin homologydomain,
but not with fragments from other regions (Figures 4D and 4E).
Conversely, FXR and the fragment (137–488), but not the frag-
ment (269–488), bound to GST-SIRT1 (Figures 4F and 4G). The
FXR region from residues (137–269) required for interaction
with SIRT1 contains both K157/K217 acetylation sites. These
results show that FXR interacts directly with SIRT1.
To test whether SIRT1 can deacetylate FXR, we performed
in vitro deacetylation studies. 3H-labeled acetylated GST-FXR
levels were decreased by incubation with GST-SIRT1 in an
NAD+-dependent manner (Figures 4H and S10). To determine
whether SIRT1 decreases FXR acetylation levels in cells,
increasing amounts of SIRT1 or a catalytically inactive SIRT1
mutant were cotransfected with expression plasmids for flag-
Figure 4. SIRT1 Directly Interacts with and
Deacetylates FXR
(A–C) Mice were fed normal or CA chow (+) for 6 hr
(A) or were treated with vehicle () or GW4064 (+)
for 1 hr (B) or were fasted (fs) overnight or refed (fd)
after overnight fasting (C). CoIP studies were
performed to examine FXR/SIRT1 interaction.
(D) Schematic diagrams of GST-SIRT1 full-length
(FL) and deletion mutants. The gray shaded area
represents the sirtuin homology domain.
(E) 35S-FXR was synthesized in vitro, and GST
pull-down assays were performed.
(F) A schematic diagram of FXR acetylation sites.
(G) 35S-FXR full-length wild-type and mutants
were synthesized, and binding to GST-SIRT1
fusion proteins was determined.
(H) GST-FXR, which had been acetylated using
p300 with 3H-acetyl CoA, was incubated with
eluted GST or GST-SIRT1 and analyzed by
SDS-PAGE followed by fluorography.
(I) Cos-1 cells were cotransfected with the indi-
cated plasmids and treated with deacetylase
inhibitors for 3 hr. Flag-FXR levels were immuno-
precipitated, and acetylated flag-FXR was
detected by western analysis. Acetylated flag-
FXR and IgG heavy chain are indicated by arrow
and asterisk, respectively. SIRT1 and flag-FXR
levels in input are shown.
FXR and p300. FXR acetylation levels
weredecreasedbySIRT1,whereas levels
werenotdecreased in cells cotransfected
with the SIRT1 mutant (Figure 4I). These
results indicate that SIRT1 directly inter-
acts with and deacetylates FXR.
FXR Agonist Treatment Results in
Dissociation of SIRT1 from the Shp
Promoter
To determine whether FXR and SIRT1
interact at the promoters of FXR target
genes in vivo, we performed chromatin immunoprecipitation
(ChIP) assays in mouse liver using the Shp gene as a model.
As reported (Fang et al., 2008; Goodwin et al., 2000; Lu
et al., 2000), GW4064 treatment increased Shp mRNA levels
about 8-fold (Figure S11). Association of SIRT1 with the
promoter was detected, and GW4064 treatment resulted in
dissociation of SIRT1 and recruitment of p300, consistent
with the observed increases in histone H3 acetylation at
K9/K14, a gene activation histone modification (Figure 5A).
Similarly, the amount of SIRT1 associated with the promoter
was significantly reduced in mice fed CA chow (Figures 5B
and 5C). These results indicate that the recruitment of SIRT1
to the Shp promoter is decreased by treatment with GW4064
or CA.(D and E) Purified flag-FXR was incubated with p300 (± acetyl CoA). In (D), acetylated flag-FXR was detected by western analysis. In (E), increasing amounts of
unacetylated or acetylated flag-FXR were incubated with purified RXRa, and the complexes were detected.
(F and G) Cos-1 cells were cotransfected with expression plasmids as indicated with p300 plasmids, and expressed protein levels were determined. Interaction
between flag-FXR and RXRa was detected by CoIP assays.Cell Metabolism 10, 392–404, November 4, 2009 ª2009 Elsevier Inc. 397
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FXR Acetylation in Normal and Disease StatesFigure 5. SIRT1 and p300 Reciprocally Regulate FXR Activity
(A–C) Mice were treated with vehicle () or GW4064 (+) for 3 hr (A) or fed CA chow for 6 hr (B). Livers were collected for ChIP assay. (C) Band intensities
were quantified using ImageJ, and the values for control samples were set to 1. The SEM is indicated, and statistical significance was determined by Student’s
t test. n = 3.
(D–F) HepG2 cells were infected with control Ad-empty or Ad-SIRT1, and 24 hr later, cells were treated with GW4064 for 1 hr, and ChIP assays were performed. In
(F), relative recruitment of FXR and RXRa was determined as described in (C). *p < 0.05; **p < 0.01.
(G) HepG2 cells were transfected with plasmids as indicated and then infected with adenoviral vectors as indicated. Cells were treated with GW4064, and CoIP
assays were performed.
(H and I) Transfected HepG2 cells were further infected with Ad-flag-FXR and then treated with CHX for indicated times.
(J and K) HepG2 cells transfected with indicated plasmids were treatedwith FXR agonists overnight, and reporter assayswere performed. Themean and SEMare
shown. n = 3.398 Cell Metabolism 10, 392–404, November 4, 2009 ª2009 Elsevier Inc.
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with the Promoter
Acetylation of FXR inhibited its interaction with RXRa and binding
ofFXR/RXRaheterodimer to theDNA (Figure3). Therefore, deace-
tylation of FXR by SIRT1 should increase binding of this hetero-
dimer to the promoter. Indeed, adenoviral-mediated overexpres-
sion of flag-SIRT1 significantly increased association of FXR and
RXRa with the SHP promoter chromatin in cells treated with
GW4064 (Figures 5D–5F). Further, in CoIP assays, interaction of
FXR with RXRa was substantially increased in cells overexpress-
ing SIRT1 (Figure 5G). Consistent with the histone deacetylation
activity of SIRT1 (Vaquero et al., 2006), acetylated H3 levels were
substantially decreased in cells overexpressing SIRT1 (Figure 5E).
These results demonstrate that SIRT1 increases FXR/RXRa
interaction and binding of this heterodimer to the promoter
chromatin.
SIRT1 Decreases the Stability of FXR
Mutation of K157 and K217 reduced acetylation of FXR and
decreased its stability (Figure 2C); therefore, deacetylation of
FXR by SIRT1 should destabilize FXR. As expected, expression
of SIRT1 increased the degradation rate of FXR (Figures 5H, 5I,
and S12). These results suggest that SIRT1 deacetylates FXR,
which increases the degradation of FXR in hepatocytes.
SIRT1 and p300 Reciprocally Modulate FXR
Transactivation
In previous cell-based reporter studies, we observed that p300
increased FXR transactivation of the SHP gene (Fang et al.,
2008). Therefore, a deacetylase, such as SIRT1, should have the
opposite effect. Consistent with previous studies, cotransfection
of increasing amounts of expression plasmids for p300, but not
of the inactive p300 mutant, increased FXR transactivation
(Figure 5J, lanes 3–9). In contrast, increasing amounts of SIRT1
progressively decreased the p300-enhanced transactivation,
whereas an inactive SIRT1 mutant had smaller effects (Figure 5J,
lanes 6 and 10–15). Similar results were observed with the natural
Shp promoter-luc reporter (Figure 5K). These data, together with
acetylation studies and chromatin IP studies, suggest that p300
and SIRT1 reciprocally regulate FXR activity bymodulating acety-
lation levels of both FXR and histones. Acetylation of histones at
the promoter is likely responsible for increased gene transcription.
In contrast, the increased acetylation of FXR by p300 may act to
limit and reverse the increased transactivation by inhibiting the
interaction with RXRa and binding to DNA.
Downregulation of SIRT1 Increases FXR Acetylation
with Deleterious Metabolic Outcomes
To directly determine whether acetylation levels of FXR in vivo
are dependent on SIRT1, we infected mice with Ad-siSIRT1
to downregulate SIRT1. Endogenous SIRT1 mRNA and protein
levels were decreased by siSIRT1 expression (Figures 6A, 6B,
and 6E). Acetylation levels of endogenous hepatic FXR were
markedly elevated in mice infected with Ad-siSIRT1
(Figure 6C). Furthermore, the interaction of endogenous FXR
with RXRa in these mice was decreased as expected upon
increased FXR acetylation (Figure 6D). Also consistent with
results from cell studies (Figure 5),ShpmRNA levels were slightly
but significantly increased in mice infected with Ad-siSIRT1Cell M(Figure 6E). Because overexpression of SIRT1 or SIRT1 activa-
tion by resveratrol, a polyphenolic SIRT1 activator, showed
beneficial gene expression patterns and improved metabolic
profiles (Baur et al., 2006; Lagouge et al., 2006; Rodgers and
Puigserver, 2007), its downregulation would be expected to
have deleterious effects. Indeed, downregulation of SIRT1 re-
sulted in increased mRNA levels of SREBP-1c and FAS involved
in hepatic lipogenesis and decreasedmRNA levels of SR-B1 and
ABCA1 involved in cholesterol transport (Figure 6E). We and
others showed that PGC-1a is an important coactivator for regu-
lation of theCyp7a1 andCyp8b1 genes (Bhalla et al., 2004; Miao
et al., 2006; Shin et al., 2003), which encode key enzymes in
hepatic bile acid biosynthesis. Consistent with these findings,
mRNA levels of Cyp7a1 and Cyp8b1 were significantly
decreased in mice infected with Ad-siSIRT1 (Figure 6E). The
mRNA levels of hepatic bile acid transporters, BSEP and
MRP2, were significantly decreased. The bile acid pool size
was also decreased as expected from these changes in gene
expression (Figure 6F). Serum VLDL and LDL levels were signif-
icantly elevated, and HDL levels were markedly decreased,
leading to a deleterious proatherogenic serum lipid profile (Fig-
ure 6G). These results indicate that SIRT1 decreases FXR acet-
ylation levels in vivo and further support the idea that decreased
SIRT1 activity and elevated FXR acetylation correlate with dele-
terious metabolic outcomes.
Elevated FXR Acetylation Levels in Metabolic
Disease Mice
To test whether acetylated FXR levels are altered in metabolic
disease states, we performed acetylation studies in two mouse
models of obesity and type II diabetes, the leptin-deficient
ob/ob mice and mice fed chronic western-style diet (WD). Acet-
ylation of FXR was substantially increased in the ob/ob mice,
although the acetylated FXR was barely separated from a strong
nonspecific band due to IgG (Figures 6H and 6I). To reduce the
amount of the IgG band, we eluted flag-FXR bound to M2
agarose using flag-peptide, and again, the level of acetylated
flag-FXR was substantially higher in the ob/ob mice (Figure S13).
Consistent with elevated FXR acetylation levels, the interaction
of FXR with p300 was increased, whereas interaction with
SIRT1 was decreased in ob/ob mice (Figure 6J). Elevated FXR
acetylation levels were also detected in mice chronically fed
WD compared to mice fed normal chow (Figure S14). Because
acetylated FXR levels were elevated in two different mouse
models of metabolic diseases, it is consistent with the idea
that elevated FXR acetylation underlie metabolic disorders.
FXR Acetylation Levels in Normal Physiology
and Pathophysiology
Finally, we compared the modulation of FXR acetylation by
normal physiological stimuli, fasting and feeding, and by meta-
bolic disease conditions using WD mice as a model. FXR acety-
lation levels were slightly but significantly increased inmice refed
after overnight fasting (Figures 6K and 6L). Remarkably, FXR
acetylation levels were dramatically elevated in WD mice
compared to mice fed normal chow (Figures 6K and 6L). Consis-
tent with roles of SIRT1 in FXR deacetylation from cell studies
(Figure 4), hepatic overexpression of SIRT1 in these WD mice
substantially reduced the FXR acetylation levels (Figure 6M).etabolism 10, 392–404, November 4, 2009 ª2009 Elsevier Inc. 399
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FXR Acetylation in Normal and Disease StatesFigure 6. Elevated FXR Acetylation Levels in Metabolic Disease States
(A–G) Mice were infected with either Ad-empty or Ad-siSIRT1, which expresses SIRT1 siRNA.
(A) Experimental outlines.
(B) Levels of endogenous SIRT1 and exogenous GFP were detected. Results from two mice are shown.
(C) Endogenous FXR was immunoprecipitated, and acetylated FXR was detected. Results from two mice are shown.
(D) CoIP assays to detect FXR/RXRa interaction.
(E) The mRNA levels of the indicated genes were determined by q-RTPCR. The mean and SEM are shown. n = 3.400 Cell Metabolism 10, 392–404, November 4, 2009 ª2009 Elsevier Inc.
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FXR Acetylation in Normal and Disease StatesTreatment with resveratrol resulted in beneficial gene expres-
sion patterns and improved an overall metabolic outcome, partly
due to deacetylation of PGC-1a inmetabolic diseasemodelmice
(Baur et al., 2006; Lagouge et al., 2006). It is possible that activa-
tion of SIRT1 might also decrease the abnormally high levels of
acetylated FXR in these disease models, which could contribute
to the beneficial effects. To test this possibility, ob/ob mice were
treated daily with resveratrol for 1 week, and acetylated FXR
levels and metabolic studies were performed. Treatment with
resveratrol substantially decreased acetylated FXR levels in
ob/obmice (Figure 6N). Further, treatment with resveratrol signif-
icantly decreased Shp mRNA levels and elevated bile acid pool
sizes in WDmice (Figures S15 and S16). These results, together,
demonstrate that acetylated FXR levels are dynamically regu-
lated by p300 and SIRT1 under normal conditions but constitu-
tively elevated in metabolic disease model mice and further
suggest that elevated acetylated FXR levels reduce FXR activity,
which is associated with deleterious outcomes in metabolic
disease states.
DISCUSSION
We demonstrate in these studies that acetylation of FXR nor-
mally dynamically modulates its activity and that abnormally
elevated levels of acetylated FXR are present in mouse models
of metabolic disease. The level of FXR acetylation is reciprocally
regulated by the acetylase p300 and the deacetylase SIRT1. The
major site of FXR acetylated by p300 is K217 within the hinge
domain, and acetylation was also detected at K157 within the
DNA-binding domain. Mutation of K157 and K217 resulted in
decreased stability of FXR but increased heterodimerization
with RXRa, binding to DNA, and transactivation activity, indi-
cating that acetylation of FXR increases its stability but inhibits
its DNA binding and transactivation activity. Downregulation of
endogenous SIRT1 in mouse liver increased acetylation levels
of endogenous FXR, demonstrating that SIRT1 affected FXR
acetylation in vivo. Of interest, downregulation of SIRT1 was
associated with deleterious gene expression patterns and meta-
bolic outcomes. Consistent with this observation, FXR acetyla-
tion levels were highly elevated in ob/ob mice and high-fat
western-style diet mice. Furthermore, activation of SIRT1 by
treatment with resveratrol, which has been shown to improve
metabolic outcomes (Baur et al., 2006; Lagouge et al., 2006),
reduced the elevated FXR acetylation in thesemetabolic disease
mice. Our results suggest an intriguing connection betweenCell Melevated FXR acetylation and decreased FXR activity in animals
with deleterious metabolic profiles.
Based on results from the present and published studies (Fang
et al., 2008), acetylation is likely to play a complex role in gene
regulation by FXR (Figure 7). Upon activation, FXR recruits
p300 to target gene promoters, and SIRT1 is dissociated, result-
ing in increased acetylation of FXR and histones. Acetylation of
histones by p300 is associated with gene activation and is prob-
ably the major factor in the activation of the FXR target gene, as
we previously demonstrated (Fang et al., 2008). At the same
time, however, acetylation of FXR itself inhibits the activity of
FXR. This seemingly paradoxical effect may be important to limit
or terminate the response to a stimulus response, which is
essential in a dynamically regulated system. Once the acetylated
FXR is released from the promoter, FXR is deacetylated by
SIRT1, which then either interacts with RXRa and rebinds to
the DNA as a heterodimer or is degraded via the ubiquitin-pro-
teasomal degradation pathway. In the absence of further stimu-
lation, SIRT1 is recruited to the target genes by the unliganded
FXR, and histones are deacetylated so that gene expression
remains at a low basal level. Importantly, acetylation and deace-
tylation of FXR appears to be a dynamic process under normal
physiological conditions so that the activity of FXR is tightly
balanced by the opposing actions of p300 and SIRT1.
In contrast to normal mice, in mice with abnormal metabolic
profiles, such as ob/ob mice, western diet mice, or mice ex-
pressing siSIRT1, the FXR acetylation levels are constitutively
and highly elevated. The increased acetylation of FXR may be
caused by low activity of SIRT1 because downregulation of
SIRT1 in normal mice led to deleterious metabolic outcomes.
In metabolic disease states, continuously acetylated FXR would
show impaired interaction with RXRa and DNA binding of FXR/
RXRa and, subsequently, decreased FXR transactivation of its
metabolic target genes. This result suggests that the dynamic
acetylation and deacetylation of FXR in normal mice may be
required for activation of the genes, whereas continuously
elevated acetylation in the diseased states blocks activation.
Therefore, our studies provide a potential intriguing correlation
between elevated FXR acetylation, decreased FXR activities,
and deleterious metabolic effects in metabolic disease states.
The correlation of elevated FXR acetylation and metabolic
disease suggests that activation of SIRT1 should have beneficial
effects. Indeed, activation of SIRT1 by resveratrol has already
beendemonstrated to havebeneficialmetabolic effects inmouse
models ofmetabolic diseaseby enhancingmitochondria function(F) The total amount of bile acids in liver, gall bladder, and intestines was measured as described in the Experimental Procedures. Dots indicate measurements
from three mice in each group. The mean and SEM are shown. n = 3. Statistical significance was determined by Student’s t test.
(G) Serum cholesterol levels were measured, and the mean and SEM are shown. Themean and SEM are shown. n = 3. Statistical significance was determined by
Student’s t test. *p < 0.01.
(H–J) Normal or ob/ob mice were infected with Ad-flag-FXR as described in the Experimental Procedures.
(H) Flag-FXR was immunoprecipitated from liver extracts, and acetylated flag-FXR in the immunoprecipitates was detected.
(I) Band intensities of acetylated flag-FXR were quantified using ImageJ. The values from control mice were set to 1. The mean and SEM are shown. n = 4.
(J) CoIP assays were performed to detect FXR/p300 (left) and FXR/SIRT1 (right).
(K) Mice were fasted overnight or fasted overnight and then refed for 1 hr. Mice were fed either normal chow or western-style diet for 16 weeks. Acetylated endog-
enous FXR levels were detected.
(L) Band intensities of acetylated FXR were quantified, and the values from fasted mice or mice fed normal chow were set to 1. The mean and SEM are shown.
Statistical significance was determined by Student’s t test.
(M) Acetylated endogenous FXR levels were detected in western-style diet mice infected with Ad-empty or Ad-flag-SIRT1.
(N) The ob/ob mice injected with Ad-flag-FXR were treated daily with resveratrol for 1 week, and livers were collected for acetylation assays as in Figure 6H.etabolism 10, 392–404, November 4, 2009 ª2009 Elsevier Inc. 401
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FXR Acetylation in Normal and Disease StatesFigure 7. A Proposed Model of FXR Acetylation in
Normal and Disease States
(A) In normal conditions, SIRT1 and FXR are associated
with promoters of FXR target genes, such as the SHP
gene.When FXR is activated by agonists, p300 is recruited
and SIRT1 is dissociated, which results in increased acet-
ylation of histone H3 and, subsequently, transcriptional
activation. At the same time, the process for limiting the
stimulated activity is initiated by acetylation of FXR by
p300, which impairs FXR interaction with RXRa and DNA
binding, resulting in dissociation of FXR from the
promoter. Later, SIRT1 deacetylates FXR, which
decreases FXR acetylation levels. The deacetylated FXR
is either degraded via the ubiquitin-proteasomal pathway
or heterodimerizes with RXRa and rebinds to the target
gene promoter with SIRT1, resulting in deacetylation of
histones and low basal levels of gene expression. The
activity of FXR is tightly balanced by the opposing actions
of p300 and SIRT1 via FXR and histone acetylation.
(B) In contrast, in metabolic disease states, FXR acetyla-
tion levels are constitutively highly elevated, probably
due to abnormally high p300 activity and low SIRT1
activity. Constitutively elevated acetylation of FXR inhibits
FXR activity, at least in part, by inhibiting FXR interaction
with RXRa and subsequently binding of FXR/RXR to the
DNA. Deacetylation of the acetylated FXRmay be required
for its further activity in normal mice but does not occur in
the diseased mice because of low expression and activity
of SIRT1.through activation of PGC-1a (Baur et al., 2006; Lagouge et al.,
2006). Our observation that activation of resveratrol or overex-
pression of SIRT1 results in decreased acetylation of FXR in
disease model mice suggests that effects of resveratrol on FXR,
in addition toPGC-1a,mayalsocontribute to improvedmetabolic
outcomes. These results are consistent with our previous studies
showing that downregulation of p300, which should reduce acet-
ylation of FXR, altered expression of metabolic target genes
involved in lipoprotein and glucose metabolism, such that bene-
ficial lipid and glucose profiles would be expected (Fang et al.,
2008). In addition to the direct effects of SIRT1 on FXR, SIRT1
may also indirectly increase FXR activity by activating PGC-1a
(Baur et al., 2006; Rodgers et al., 2008). PGC-1a has been shown
to coactivate FXR transactivation and increase FXR expression
(Zhang et al., 2004). It is possible that SIRT1-mediated PGC-1a
coactivation and FXR deacetylation synergistically regulate
hepatic FXR activity under physiological conditions.
It has been demonstrated that bile acids not only activate FXR
signaling by binding to the ligand-binding domain of FXR, but
also activate upstream cellular kinase signaling pathways,
such as protein kinase B (PKB, Akt), PKC, JNK, and ERK kinases
in hepatocytes (Dent et al., 2005; Gineste et al., 2008; Hylemon
et al., 2009; Miao et al., 2009). We recently demonstrated that
bile acids increase the stability of SHP, a well-known FXR target,
by inhibiting ubiquitin-proteasomal degradation in an ERK-
dependent manner (Miao et al., 2009). A recent study showed
that inhibition of PKC impaired ligand-mediated regulation of
FXR activity of its target genes by blocking FXR interaction
with PGC-1a (Gineste et al., 2008). Of interest, one of the two
reported PKC sites in FXR, S154, is located near K157, an acet-402 Cell Metabolism 10, 392–404, November 4, 2009 ª2009 Elsevieylation site in FXR. Therefore, it will be interesting to know
whether phosphorylation of FXR by PKB or PKC affects acetyla-
tion of FXR and whether impaired signaling pathways are
associated with elevated FXR acetylation in metabolic disease
states.
Although K217 was identified as the major acetylation site for
FXR, acetylation at K157 was also observed. Recent studies
demonstrated that acetylation of p53 at different lysine residues
affected different biological processes; for example, acetylation
of p53 at K120 in the DNA-binding domain by Tip60 acetylase is
crucial for apoptosis but is dispensable for cell-cycle arrest
(Tang et al., 2006). Likewise, acetylation at K157 and K217 in
FXRmay have different functional outcomes andmay selectively
play a role in regulation of subsets of target genes involved in
different metabolic pathways, such as cholesterol/bile acids,
fatty acid, and glucose. Therefore, it will be important to deter-
mine whether acetylation in the disease models is generally
increased or whether acetylation at specific sites is increased
and whether FXR acetylated at different sites is recruited in a
gene-selective manner.
In this study, we demonstrate that FXR acetylation is tightly
and reciprocally regulated by p300 and SIRT1 and is critical for
activation of FXR target genes in response to FXR signaling
under normal conditions. Further, this dynamic regulation of
FXR acetylation is disrupted in metabolic disease model mice,
resulting in constitutively elevated FXR acetylation. We propose
that small molecules that inhibit FXR acetylation by increasing
SIRT1 or decreasing p300 activity may be promising therapeutic
agents for treatment of metabolic disorders, such as fatty liver,
diabetes, and obesity.r Inc.
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Materials
Antibodies against FXR, RXR, p300, GFP, lamin, tubulin, and RNA polymerase
II were purchased from Santa Cruz Biotech. M2 antibody was purchased from
Sigma and SIRT1, and acetylated H3 (K9/K14) antibodies were from Upstate
Biotech. Acetyl lysine antibody was purchased from Cell Signaling, Inc.
GW4046 was a kind gift from T.M. Willson. TSA, nicotinamide (Nam), and
resveratrol were purchased from Sigma, Inc.
Plasmid and Adenoviral Vector Constructs
Acetylation-defective and mimic flag-FXR mutants were constructed by
site-directed mutagenesis (Stratagene, Inc.) and confirmed by sequencing.
Flag-FXR in this manuscript refers to 3flag-human FXR. Ad-flag-FXR has
been previously described (Fang et al., 2008).
Animal Experiments
BALB/c male mice were fed with chow supplemented with 0.5% CA (Har-
land Teklad TD05271) for 3–6 hr or treated with GW4064 (30 mg/kg in
corn oil) by intraperitoneal injection, and 1–3 hr later, livers were collected
for further analyses. BALB/c mice were fasted overnight or refed for 1 hr
after overnight fasting, and livers were collected for further analyses. About
8- to 12-week-old ob/ob mice or congenic C57BL/6J mice were tail vein
injected with Ad-flag-FXR and then daily and orally treated with resveratrol
(50 mg/kg body weight) for 1 week. BALB/c mice were fed normal chow
or high-fat western style chow for 16 weeks and then infected with control
Ad-empty or Ad-flag-FXR or daily and orally treated with resveratrol for
1 week. Recombinant adenovirus was injected via the tail vein of mice as
previously described (Fang et al., 2007; Miao et al., 2009). All of the animal
use and adenoviral protocols were approved by the Institutional Animal Care
and Use and Institutional Biosafety Committees at University of Illinois at
Urbana-Champaign and were in accordance with National Institutes of
Health guidelines.
Tandem Mass Spectrometry Analysis
Flag-FXR was expressed in HepG2 cells (three plates of 15 cm per group) by
adenoviral infection. Flag-FXR was purified by binding to M2 agarose and
subjected to tandem mass (MS/MS) spectrometry analysis as described
previously (Miao et al., 2009).
Acetylation and Deacetylation Assays
HepG2 cells (ATCC HB8065) were maintained in Dulbecco’s modified Eagle’s
medium (DMEM)/F12 (1:1) medium. Cos-1 cells were maintained in DMEM
medium. Cells were infected with Ad-flag-FXR as previously described (Fang
et al., 2008). For acetylation assays in cells, Cos-1 cells were cotransfected
with expression plasmids of flag-FXR along with p300. Cells were treated
with 200 nM of GW4064, 500 nM of TSA, and 10 mM of Nam for 2–5 hr. Flag-
FXR or endogenous FXR in cells or mouse liver was immunoprecipitated
from freshly prepared cell or liver extracts at 4C for 2 hr in buffer (50 mM
Tris-HCl [pH 7.6], 150 mM NaCl, 5 mM EDTA, 1% NP40, and 0.1% SDS).
Acetylated FXR was detected by western analyses. For in vitro assays, acety-
lated flag-FXRorGST-flag-FXRwas incubatedwithpurifiedGSTorGST-SIRT1
in the presence of 50 mM NAD+ in deacetylation buffer (Tris-HCl [pH 8.8], 5%
glycerol, 50 mM NaCl, 4 mM MgCl2, 1 mM DTT) at 37
C for 1 hr as previously
described (Fang et al., 2008).
Protein Interaction Assays
Chromatin IP (ChIP), coimmunoprecipitation (CoIP), and GST pull-down
assays were performed as described previously (Fang et al., 2007; Kemper
et al., 2004;Miao et al., 2009). Gel mobility shift assayswere done as described
(Bhalla et al., 2004; Miao et al., 2006) with some modifications. In brief, a
26-mer oligonucleotide containing the FXRE sequence present in the SHP
promoter was labeled with g-32P and gel purified. Increasing amounts of
flag-FXR or Cos-1 whole-cell extracts were incubated with purified flag-
RXRa and incubated at RT for 10 min. The complexes were analyzed using
nondenaturing acrylamide gel electrophoresis.Cell MQuantification of mRNA
RNA was isolated from liver or cultured cells, and the levels of mRNA were
determined by quantitative reverse transcriptase-PCR (qRT-PCR) as previ-
ously described (Miao et al., 2009).
Bile Acid Pool Size and Serum Cholesterol Levels Measurement
The total amount of bile acids from gall bladder, liver, and entire intestines was
measured by colorimetric analysis (Trinity Biotech). Serum cholesterol levels
were measured using a HDL and LDL/VLDL cholesterol quantification kit
(Biovision, Inc).
SUPPLEMENTAL DATA
SupplementalData include16figures andcanbe foundwith this article onlineat
http://www.cell.com/cell-metabolism/supplemental/S1550-4131(09)00297-6.
ACKNOWLEDGMENTS
We are grateful to P. Puigserver for Ad-siSIRT1 and Ad-flag-SIRT1, P.
Edwards for FXR deletion constructs, M. Leid for GST-SIRT1 constructs, R.
Sato for plasmids CMV-3 flag-FXR and G4DBD-FXR, W. Gu and T. Finkel for
plasmids for SIRT1 WT and mutant, M. Ananthanarayanan for (FXRE)3-tk-
luc, Yoon K. Lee for the Shp-luc reporter plasmid, and T. Imamura for the
HA-Ub plasmid. Special thanks to Dr. T.M. Willson for providing GW4064.
We also thank B. Kemper for helpful discussions. This study was supported
by NIH grants CA103867 and CA124760 to C.-M.C. and NIH DK062777, NIH
DK80032, and ADA basic research award to J.K.K. This project has been
funded in whole or in part with federal funds from the National Cancer Institute,
National Institutes of Health under Contract N01-CO-12400 to T.D.V.
Received: May 5, 2009
Revised: August 7, 2009
Accepted: September 16, 2009
Published: November 3, 2009
REFERENCES
Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A.,
Prabhu, V.V., Allard, J.S., Lopez-Lluch, G., Lewis, K., et al. (2006). Resveratrol
improves health and survival of mice on a high-calorie diet. Nature 444,
337–342.
Bhalla, S., Ozalp, C., Fang, S., Xiang, L., and Kemper, J.K. (2004). Ligand-
activated pregnane X receptor interferes with HNF-4 signaling by targeting
a common coactivator PGC-1alpha. Functional implications in hepatic choles-
terol and glucose metabolism. J. Biol. Chem. 279, 45139–45147.
Cariou, B., and Staels, B. (2007). FXR: a promising target for the metabolic
syndrome? Trends Pharmacol. Sci. 28, 236–243.
Daitoku, H., Hatta, M., Matsuzaki, H., Aratani, S., Ohshima, T., Miyagishi, M.,
Nakajima, T., and Fukamizu, A. (2004). Silent information regulator 2 potenti-
ates Foxo1-mediated transcription through its deacetylase activity. Proc.
Natl. Acad. Sci. USA 101, 10042–10047.
Dent, P., Fang, Y., Gupta, S., Studer, E., Mitchell, C., Spiegel, S., and Hylemon,
P.B. (2005). Conjugated bile acids promote ERK1/2 and AKT activation via
a pertussis toxin-sensitive mechanism in murine and human hepatocytes.
Hepatology 42, 1291–1299.
Fang, S., Miao, J., Xiang, L., Ponugoti, B., Treuter, E., and Kemper, J.K. (2007).
Coordinated recruitment of histone methyltransferase G9a and other
chromatin modifying enzymes in SHP-mediated regulation of hepatic bile
acid metabolism. Mol. Cell. Biol. 27, 1407–1424.
Fang, S., Tsang, S., Jones, R., Ponugoti, B., Yoon, H., Wu, S.Y., Chiang, C.M.,
Willson, T.M., and Kemper, J.K. (2008). The P300 acetylase is critical for
ligand-activated farnesoid X receptor (FXR) induction of SHP. J. Biol. Chem.
283, 35086–35095.
Gineste, R., Sirvent, A., Paumelle, R., Helleboid, S., Aquilina, A., Darteil, R.,
Hum, D.W., Fruchart, J.C., and Staels, B. (2008). Phosphorylation of farnesoidetabolism 10, 392–404, November 4, 2009 ª2009 Elsevier Inc. 403
Cell Metabolism
FXR Acetylation in Normal and Disease StatesX receptor by protein kinase C promotes its transcriptional activity. Mol.
Endocrinol. 22, 2433–2447.
Goodwin, B., Jones, S.A., Price, R.R., Watson, M.A., McKee, D.D., Moore,
L.B., Galardi, C., Wilson, J.G., Lewis, M.C., Roth, M.E., et al. (2000). A regula-
tory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile
acid biosynthesis. Mol. Cell 6, 517–526.
Guarente, L. (2007). Sirtuins in aging and disease. Cold Spring Harb. Symp.
Quant. Biol. 72, 483–488.
Huang, W., Ma, K., Zhang, J., Qatanani, M., Cuvillier, J., Liu, J., Dong, B.,
Huang, X., and Moore, D.D. (2006). Nuclear receptor-dependent bile acid
signaling is required for normal liver regeneration. Science 312, 233–236.
Hylemon, P.B., Zhou, H., Pandak, W.M., Ren, S., Gil, G., and Dent, P. (2009).
Bile acids as regulatory molecules. J. Lipid Res. 50, 1509–1520.
Inagaki, T., Moschetta, A., Lee, Y.K., Peng, L., Zhao, G., Downes, M., Yu, R.T.,
Shelton, J.M., Richardson, J.A., Repa, J.J., et al. (2006). Regulation of antibac-
terial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl.
Acad. Sci. USA 103, 3920–3925.
Kalaany, N.Y., and Mangelsdorf, D.J. (2006). LXRS and FXR: the yin and yang
of cholesterol and fat metabolism. Annu. Rev. Physiol. 68, 159–191.
Kemper, J.K., Kim, H., Miao, J., Bhalla, S., and Bae, Y. (2004). Role of
a mSin3A-Swi/Snf chromatin remodeling complex in the feedback repression
of bile acid biosynthesis by SHP. Mol. Cell. Biol. 24, 7707–7719.
Kitamura, Y.I., Kitamura, T., Kruse, J.P., Raum, J.C., Stein, R., Gu, W., and
Accili, D. (2005). FoxO1 protects against pancreatic beta cell failure through
NeuroD and MafA induction. Cell Metab. 2, 153–163.
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin,
F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006). Resveratrol
improves mitochondrial function and protects against metabolic disease by
activating SIRT1 and PGC-1alpha. Cell 127, 1109–1122.
Lee, F.Y., Lee, H., Hubbert, M.L., Edwards, P.A., and Zhang, Y. (2006). FXR,
a multipurpose nuclear receptor. Trends Biochem. Sci. 31, 572–580.
Lerin, C., Rodgers, J.T., Kalume, D.E., Kim, S.H., Pandey, A., and Puigserver,
P. (2006). GCN5 acetyltransferase complex controls glucose metabolism
through transcriptional repression of PGC-1alpha. Cell Metab. 3, 429–438.
Li, X., Zhang, S., Blander, G., Tse, J.G., Krieger, M., and Guarente, L. (2007).
SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol.
Cell 28, 91–106.
Lu, T.T., Makishima, M., Repa, J.J., Schoonjans, K., Kerr, T.A., Auwerx, J., and
Mangelsdorf, D.J. (2000). Molecular basis for feedback regulation of bile acid
synthesis by nuclear receptors. Mol. Cell 6, 507–515.
Luo, J., Nikolaev, A.Y., Imai, S., Chen, D., Su, F., Shiloh, A., Guarente, L., and
Gu, W. (2001). Negative control of p53 by Sir2alpha promotes cell survival
under stress. Cell 107, 137–148.
Ma, K., Saha, P.K., Chan, L., and Moore, D.D. (2006). Farnesoid X receptor is
essential for normal glucose homeostasis. J. Clin. Invest. 116, 1102–1109.
Mangelsdorf, D.J., and Evans, R.M. (1995). The RXR heterodimers and orphan
receptors. Cell 83, 841–850.404 Cell Metabolism 10, 392–404, November 4, 2009 ª2009 ElsevierMiao, J., Fang, S., Bae, Y., and Kemper, J.K. (2006). Functional inhibitory
cross-talk between car and HNF-4 in hepatic lipid/glucose metabolism is
mediated by competition for binding to the DR1 motif and to the common
coactivators, GRIP-1 and PGC-1alpha. J. Biol. Chem. 281, 14537–14546.
Miao, J., Xiao, Z., Kanamaluru, D., Min, G., Yau, P.M., Veenstra, T.D., Ellis, E.,
Strom, S., Suino-Powell, K., Xu, H.E., and Kemper, J.K. (2009). Bile acid
signaling pathways increase stability of Small Heterodimer Partner (SHP) by
inhibiting ubiquitin-proteasomal degradation. Genes Dev. 23, 986–996.
Motta, M.C., Divecha, N., Lemieux, M., Kamel, C., Chen, D., Gu, W., Bultsma,
Y., McBurney, M., and Guarente, L. (2004). Mammalian SIRT1 represses
forkhead transcription factors. Cell 116, 551–563.
Rodgers, J.T., and Puigserver, P. (2007). Fasting-dependent glucose and lipid
metabolic response through hepatic sirtuin 1. Proc. Natl. Acad. Sci. USA 104,
12861–12866.
Rodgers, J.T., Lerin, C., Haas, W., Gygi, S.P., Spiegelman, B.M., and Puig-
server, P. (2005). Nutrient control of glucose homeostasis through a complex
of PGC-1alpha and SIRT1. Nature 434, 113–118.
Rodgers, J.T., Lerin, C., Gerhart-Hines, Z., and Puigserver, P. (2008). Meta-
bolic adaptations through the PGC-1 alpha and SIRT1 pathways. FEBS Lett.
582, 46–53.
Rosenfeld, M.G., Lunyak, V.V., and Glass, C.K. (2006). Sensors and signals:
a coactivator/corepressor/epigenetic code for integrating signal-dependent
programs of transcriptional response. Genes Dev. 20, 1405–1428.
Shin, D.J., Campos, J.A., Gil, G., and Osborne, T.F. (2003). PGC-1alpha acti-
vates CYP7A1 and bile acid biosynthesis. J. Biol. Chem. 278, 50047–50052.
Sinal, C.J., Tohkin, M., Miyata, M.,Ward, J.M., Lambert, G., andGonzalez, F.J.
(2000). Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid
and lipid homeostasis. Cell 102, 731–744.
Sinclair, D.A., Lin, S.J., and Guarente, L. (2006). Life-span extension in yeast.
Science 312, 195–197.
Tang, Y., Luo, J., Zhang, W., and Gu, W. (2006). Tip60-dependent acetylation
of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol.
Cell 24, 827–839.
Vaquero, A., Scher, M.B., Lee, D.H., Sutton, A., Cheng, H.L., Alt, F.W.,
Serrano, L., Sternglanz, R., and Reinberg, D. (2006). SirT2 is a histone deace-
tylase with preference for histone H4 Lys 16 during mitosis. Genes Dev. 20,
1256–1261.
Willson, T.M., Jones, S.A., Moore, J.T., and Kliewer, S.A. (2001). Chemical
genomics: functional analysis of orphan nuclear receptors in the regulation
of bile acid metabolism. Med. Res. Rev. 21, 513–522.
Zhang, Y., Castellani, L.W., Sinal, C.J., Gonzalez, F.J., and Edwards, P.A.
(2004). Peroxisome proliferator-activated receptor-gamma coactivator 1alpha
(PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear
receptor FXR. Genes Dev. 18, 157–169.
Zhang, Y., Lee, F.Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F.J., Willson,
T.M., and Edwards, P.A. (2006). Activation of the nuclear receptor FXR
improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl.
Acad. Sci. USA 103, 1006–1011.Inc.
